Cite

Copy

Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Install/Install App' to create a shortcut app

Outcome of Treatments for Supratentorial Meningiomas in Children

This page was last updated on May 9th, 2017

Outcome is mostly influenced by location, pathology, degree of resection, and associated risk factors such as NF2 and prior radiation. As discussed previously, the series tend to be small, and there is a good deal of variability in the literature.

  • 0 – 8% mortality rate: The surgical mortality rate is 0  -8%, depending on the series (1, 6).
  • 33% recurrence: The recurrence rate is approximately 33% at 10 years for completely resected lesions, and an incidence of progression is 80% for subtotally resected lesions. The general trends seem to indicate that the classic benign meningioma that can be completely resected has a low recurrence rate and behaves similarly to adult lesions. Because children tend to have more malignant tumors, most series report more dismal overall outcomes in children (1,2,6).
  • Poor prognosis predictors: Incomplete resection or malignant pathology, or association with NF2 or prior radiation, will significantly increase the risk of recurrence (5).

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.